Virbac Sa Stock Beta
| VIRP Stock | EUR 324.00 3.00 0.93% |
Virbac SA fundamentals help investors to digest information that contributes to Virbac SA's financial success or failures. It also enables traders to predict the movement of Virbac Stock. The fundamental analysis module provides a way to measure Virbac SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Virbac SA stock.
Virbac |
Virbac SA Company Beta Analysis
Virbac SA's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Virbac SA Beta | 0.88 |
Most of Virbac SA's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virbac SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Virbac SA has a Beta of 0.8822. This is 2.58% higher than that of the Healthcare sector and 24.6% lower than that of the Drug Manufacturers - Major industry. The beta for all France stocks is notably lower than that of the firm.
Virbac Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virbac SA's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Virbac SA could also be used in its relative valuation, which is a method of valuing Virbac SA by comparing valuation metrics of similar companies.Virbac SA is currently under evaluation in beta category among its peers.
Virbac SA returns are very sensitive to returns on the market. As the market goes up or down, Virbac SA is expected to follow.
Virbac Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.091 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 2 B | |||
| Shares Outstanding | 8.44 M | |||
| Shares Owned By Insiders | 50.38 % | |||
| Shares Owned By Institutions | 25.03 % | |||
| Price To Earning | 70.83 X | |||
| Price To Book | 2.47 X | |||
| Price To Sales | 1.76 X | |||
| Revenue | 1.06 B | |||
| Gross Profit | 712.85 M | |||
| EBITDA | 201.66 M | |||
| Net Income | 113.16 M | |||
| Cash And Equivalents | 63.55 M | |||
| Cash Per Share | 7.55 X | |||
| Total Debt | 13.15 M | |||
| Debt To Equity | 98.40 % | |||
| Current Ratio | 1.23 X | |||
| Book Value Per Share | 96.99 X | |||
| Cash Flow From Operations | 129.9 M | |||
| Earnings Per Share | 14.05 X | |||
| Target Price | 311.6 | |||
| Number Of Employees | 5.12 K | |||
| Beta | 0.88 | |||
| Market Capitalization | 2.4 B | |||
| Total Asset | 1.2 B | |||
| Retained Earnings | 163 M | |||
| Working Capital | 122 M | |||
| Current Asset | 486 M | |||
| Current Liabilities | 364 M | |||
| Annual Yield | 0 % | |||
| Five Year Return | 1.09 % | |||
| Net Asset | 1.2 B | |||
| Last Dividend Paid | 1.25 |
About Virbac SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virbac SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virbac SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virbac SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Virbac Stock
Virbac SA financial ratios help investors to determine whether Virbac Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Virbac with respect to the benefits of owning Virbac SA security.